This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Japan Tobacco Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Yoshihiro Kitagawa
Introduction: Yoshihiro Kitagawa, an accomplished inventor based in Takatsuki, Japan, has made significant strides in the field of medicinal chemistry. With a keen focus on therapeutic solutions, his work primarily revolves around innovative methods for treating pain, including conditions like interstitial cystitis.
Latest Patents: Kitagawa holds a noteworthy patent for a method of treating pain or interstitial cystitis using an indole compound. This patent outlines a therapeutic or prophylactic agent comprising N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide, or a pharmaceutically acceptable salt thereof. This innovation represents a significant advancement in the treatment possibilities for patients suffering from these conditions.
Career Highlights: Kitagawa is associated with Japan Tobacco Inc., where he has contributed to the company's research and development efforts. His background and expertise in medicinal applications help in the formulation of effective treatments aimed at improving patient care.
Collaborations: Throughout his career, Kitagawa has worked alongside talented colleagues such as Yoshifumi Ueda and Mutsuyoshi Matsushita. These collaborations have undoubtedly enriched his research, leading to innovative solutions in pain management and related therapeutic areas.
Conclusion: Yoshihiro Kitagawa exemplifies the spirit of innovation within the pharmaceutical sector. His dedication to developing new treatments for pain and interstitial cystitis is commendable. The impact of his work continues to resonate within the medical community, promising hope for many individuals affected by these conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
